TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04332315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginally assisted laparoscopic sacrocolpopexy
Description: The VALS procedure consists of two steps. First, vaginal hysterectomy or laparoscopically assisted vaginal hysterectomy performed, anterior vaginal wall dissected up to bladder neck starting from initial vaginal incision, posterior vaginal wall dissected from rectum starting from initial vaginal incision up to distal third of posterior vaginal wall.The free arms of fixed meshes are introduced to the peritoneal cavity and the vaginal vault is closed with absorbable polyglactin suture. laparoscopy phase was performed with one intraumbilical (10 mm), 3 lateral abdominal (5 mm) trocars. Two mesh strips fixated to anterior longitudinal ligament of the sacrum with two separate no: 1 polypropylene sutures without tension.~AS was performed via Pfannenstiel incision after total or subtotal abdominal hysterectomy
Study: NCT01153997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Study: NCT04009681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor
Description: Pharmaceutical form: solution for IV administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor
Description: Pharmaceutical form: solution for IV administration; Route of administration: IV administration
Study: NCT02620592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYDPLA1 tablet
Description: The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
Study: NCT02922335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy for Emerging Adults
Description: MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
Study: NCT04009681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor
Description: Pharmaceutical form: solution for IV administration; Route of administration: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR antibody
Description: Pharmaceutical form: solution for IV administration; Route of administration: IV administration
Study: NCT02922335

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
Study: NCT03851562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil 20 micrograms
Description: Intravenous infusion of PGE1 (Days 0, +1 and +2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of physiological saline solution
Study: NCT02804295

Intervention type: OTHER
Group type: OTHER
Intervention: Collaborative Care Intervention
Description: All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
Study: NCT03863821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT
Study: NCT01735136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InSan Bamboo Salt
Description: InSan Bamboo Salt (10g/day)
Study: NCT02881684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration Therapy (AspireAssist®)
Description: Use of the AspireAssist device in aspiration therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration Therapy (AspireAssist®)
Description: Use of the AspireAssist device in aspiration therapy
Study: NCT04459949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sharkskin
Description: Use of Sharkskin ILM forceps
Study: NCT02881684

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program
Study: NCT03370640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: An oral 25 or 50mg dose of SEP 363856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: An oral 25 or 50mg dose of SEP 363856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: An oral 25 or 50mg dose of SEP 363856
Study: NCT02585908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Description: CIK cells will be used against tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T
Description: γδ T cells will be used against tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK and γδ T
Description: CIK and γδ T cells will be used against tumor cells.
Study: NCT02138877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: After coming stent after dismembered pyeloplasty
Description: Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stentless dismembered pyeloplasty
Description: Dismembered pyeloplasty through lumbar incision. No stents are inserted
Study: NCT01228058

Intervention type: PROCEDURE
Intervention: RapidTEG test
Description: The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
Study: NCT04122521

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI
Study: NCT01924689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium novyi-NT spores
Description: Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
Study: NCT00739752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed-Recommended
Description: Subjects receive loss-framed messages and are recommended the vaccine.
Study: NCT04413578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Contour NextOne
Description: A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
Study: NCT02745964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA supreme
Description: Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
Study: NCT01825408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
Study: NCT02149342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexylaminolaevulinate cream
Description: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylaminolaevulinate cream
Description: MAL 16% is used as photosensitizer for daylight-PDT
Study: NCT01331694

Intervention type: DRUG
Intervention: fluticasone/salmeterol combination (FSC) 250/50mcg
Description: patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg

Intervention type: DRUG
Intervention: tiotropium
Description: patients initiating treatment with tiotropium

Intervention type: DRUG
Intervention: ipratropium bromide alone or in fixed dose combination with albuterol
Description: patients initiating treatment with ipratropium/albuterol
Study: NCT04138615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study: NCT03493334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual feedback
Description: Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No visual feedback
Description: Participants will be asked to perform active movements of their neck with the mirrors covered.
Study: NCT01735136

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (10g/day)
Study: NCT02808559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodystudio ATBM (Automatic Total Body Mapping)
Description: The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
Study: NCT02277665

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CUD Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CUD Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment
Study: NCT03704285

Intervention type: DRUG
Intervention: Propofol
Description: Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.

Intervention type: DEVICE
Intervention: BIS
Description: GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
Study: NCT01961310

Intervention type: BIOLOGICAL
Intervention: Plasma analysis for bacterial translocation
Description: 1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.

Intervention type: BIOLOGICAL
Intervention: Plasma analysis for bacterial translocation
Description: 1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
Study: NCT01856816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Pattern Treatment A
Description: In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals.
Study: NCT01961310

Intervention type: BIOLOGICAL
Intervention: Stool analysis
Description: DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.

Intervention type: BIOLOGICAL
Intervention: Stool analysis
Description: DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
Study: NCT00761969

Intervention type: OTHER
Intervention: Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice
Description: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.

Intervention type: OTHER
Intervention: Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice
Description: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
Study: NCT02261558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Improvisation Instrumental Music Therapy
Description: Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Vocal Improvisation
Description: \* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
Study: NCT00977171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
Study: NCT01727596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taping
Description: Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
Study: NCT00412893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
Study: NCT03833869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Description: Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
Study: NCT02737475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT04335513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early CGM-guided education and initiation of insulin therapy.
Description: Careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, staged education targeted to assist families in recognizing evolving dysglycemia, and addressing glycemic abnormalities with early initiation of insulin can substantially reduce the HbA1c and risk of DKA at diagnosis, thereby changing the trajectory of the disease course.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care: glucometer surveillance and basic education.
Description: * Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK.~* Blinded CGM for 10 days every 3 months to collect data on glycemic profile with basic feedback regarding changes.
Study: NCT03221647

Intervention type: OTHER
Intervention: Intestinal biopsies
Description: Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.

Intervention type: OTHER
Intervention: Intestinal biopsies
Description: Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.

Intervention type: OTHER
Intervention: Intestinal biopsies
Description: Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
Study: NCT00942084

Intervention type: DRUG
Group type: OTHER
Intervention: Acyclovir
Description: Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).
Study: NCT04459949

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Grieshaber
Description: Use of Grieshaber ILM forceps
Study: NCT01478256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Topical erythromycin ointment twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifloxocin
Description: Topical Besifloxocin twice a day
Study: NCT02458794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: function tests
Description: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: function tests
Description: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA SupremeTM